Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands

IMPORTANCE: The number of new cancer medicines that are being approved by regulatory agents is increasing exponentially. Yet little is known about the pace at which these medicines reach eligible patients in daily clinical practice during different phases of the postapproval access pathway. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Luyendijk, Marianne, Blommestein, Hedwig, Uyl-de Groot, Carin, Siesling, Sabine, Jager, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936344/
https://www.ncbi.nlm.nih.gov/pubmed/36795415
http://dx.doi.org/10.1001/jamanetworkopen.2022.56170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936344/
https://www.ncbi.nlm.nih.gov/pubmed/36795415
http://dx.doi.org/10.1001/jamanetworkopen.2022.56170

Ejemplares similares